Skip links
OncoOne

Strategic Partnerships

Expanding next-generation radiopharmaceutical therapies through strategic partnerships.

The PreTarg-it® platform enables flexible development of pretargeted radioimmunotherapies across oncology indications.

OncoOne collaborates with pharmaceutical and biotechnology partners to co-develop and advance innovative radiopharmaceutical therapies toward clinical application.

Structured for Precision. Built for Translation.

Why Partner with OncoOne?

Pretargeted Radionuclide Therapy

Sequential targeting
enables controlled,
localized radiation
delivery to tumors.

Modular
Platform Integration

Flexible combination of antibody-based targeting entities with diverse radionuclides.

Expandable Across Indications

Scalable design supports expansion across multiple targets and oncology indications.

Partnership Focused Development

Collaborative models
align with partner
technologies and
strategic priorities.

Why Partner with OncoOne?

Pretargeted Radionuclide Therapy

Sequential targeting enables controlled, localized radiation delivery to tumors.

Modular
Platform Integration

Flexible combination of antibody-based targeting entities with diverse radionuclides.

Expandable Across Indications

Scalable design supports expansion across multiple targets and oncology indications.

Partnership Focused Development

Collaborative models align with partner technologies and strategic priorities.

Collaboration Opportunities

Co-Development & Licensing

Pipeline Programs
Strategic partnerships to advance preclinical pipeline programs efficiently toward clinical development.

Target Expansion Programs
Joint development of pretargeted radioimmunotherapy programs incorporating partner-defined targets.

Platform-Based Strategic Alliances

Partnering to combine the PreTarg-it® platform with complementary technologies, including:

• tumor-targeting entities
• radionuclides and other payloads
• radiopharmaceutical development capabilities

Work With OncoOne

Advancing pretargeted radiopharmaceutical therapies together.
Our science-driven collaborations accelerate clinical translation and expand the PreTarg-it® platform across oncology indications.
Partner with Us